Updated data from the phase 1/II BRUIN trial of Jaypirca in patients with covalent BTK inhibitor pre-treated r/r Mantle Cell Lymphoma continue to demonstrate durable efficacy – Eli Lilly
A poster presentation (Abstract #7514) presented at ASCO will highlight efficacy data with a median survival follow-up time of two years for Jaypirca in relapsed or refractory MCL… read more.
